Education
About Us
Working with TipRanks
Follow Us
Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
RESEARCH TOOLSreports
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.79B | $ 2.39B | $ 2.21B | $ 2.09B | $ 1.99B |
| Gross Profit | $ 1.02B | $ 820.57M | $ 784.71M | $ 768.97M | $ 628.39M |
| Operating Income | $ 249.33M | $ 204.37M | $ 206.46M | $ 209.24M | $ 91.16M |
| EBITDA | $ 439.77M | $ 399.76M | $ 150.43M | $ 450.00M | $ 381.05M |
| Net Income | $ -116.89M | $ -83.99M | $ -254.79M | $ 20.17M | $ 68.58M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 110.55M | $ 91.54M | $ 25.98M | $ 247.79M | $ 341.38M |
| Total Assets | $ 3.50B | $ 3.47B | $ 3.80B | $ 3.94B | $ 4.01B |
| Total Debt | $ 331.35M | $ 2.75B | $ 2.85B | $ 2.88B | $ 2.94B |
| Net Debt | $ 220.80M | $ 2.66B | $ 2.82B | $ 2.63B | $ 2.60B |
| Total Liabilities | $ 3.61B | $ 3.45B | $ 3.59B | $ 3.57B | $ 3.66B |
| Stockholders' Equity | $ -109.27M | $ 19.78M | $ 183.98M | $ 366.97M | $ 344.93M |
| Cash Flow | |||||
| Free Cash Flow | $ 243.18M | $ 276.39M | $ -25.50M | $ 189.18M | $ 312.81M |
| Operating Cash Flow | $ 295.10M | $ 345.58M | $ 65.10M | $ 241.82M | $ 379.00M |
| Investing Cash Flow | $ -63.00M | $ -69.19M | $ -174.31M | $ -194.18M | $ -317.55M |
| Financing Cash Flow | $ -211.79M | $ -212.57M | $ -106.62M | $ -138.12M | $ 131.81M |